Bromide

Bromide

SCHEMBL23858158

Cc1c[n+](Cc2ccccc2)ccc1Br.[Br-]

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CHKA known ✓ P35790 8/20 0.49
▸ ACHE known ✓ P22303 4/20 0.47
▸ ALDH1A1 P00352 3/20 0.49
▸ LMNA P02545 3/20 0.49
▸ HTT P42858 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ BCHE P06276 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL15821503 0.86 ACHE (0.50) CHKAALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL15836459 0.84 ALDH1A1 (0.49) CHKAALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL5307716 0.82 ALDH1A1 (0.53) CHKAALDH1A1LMNAHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL7307884 0.80 ALDH1A1 (0.56) CHKAALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL31652036 0.76 ACHE (0.48) CHKAALDH1A1LMNAHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL19468916 0.76 ALDH1A1 (0.51) CHKAALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL19601104 0.75 ALDH1A1 (0.58) CHKAALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL25848023 0.74 LMNA (0.47) CHKAALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL28927098 0.74 ACHE (0.51) CHKAALDH1A1LMNAHTTSMN1; SMN2
Bromide SCHEMBL1757103 0.74 ALDH1A1 (0.72) CHKAALDH1A1LMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115362151-B Arylpiperidines as monoacylglycerol lipase modulators 詹森药业有限公司 2025-02-11 — — CN disclosed
US-20240092781-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-03-21 — — US disclosed
US-11787798-B2 Aryl piperidines as monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-17 — — US disclosed
EP-4126840-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica NV (BE) 2023-02-08 — — EP disclosed
CN-115362151-A Aryl piperidines as monoacylglycerol lipase modulators 詹森药业有限公司 2022-11-18 — — CN disclosed
US-20220363679-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-11-17 — — US disclosed
WO-2021191384-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092781-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP CHKA 1927/4885ACHE 45/4885ALDH1A1 102/4885
US-11787798-B2 Aryl piperidines as monoacylglycerol lipase modulators MGLL, LPL, PNLIP CHKA 1927/4885ACHE 45/4885ALDH1A1 102/4885
US-20220363679-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP CHKA 1927/4885ACHE 45/4885ALDH1A1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback